First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a named patient (early...

Related Keywords

Canada ,Melbourne ,Victoria ,Australia ,Japan ,United Kingdom ,Belgium ,Switzerland ,Netherlands ,United States ,Dutch ,The Netherlands ,Australian ,Peter Mulders ,Kyahn Williamson ,Radboud University Medical Centre Netherlands ,Australian Therapeutic Goods Administration ,Radboud University Medical Centre In Nijmegen ,Corporate Communications ,Australian Securities Exchange ,Dutch Health Inspectorate ,Drug Administration ,Health Canada ,Telix Pharmaceuticals ,Prnewswire Telix Pharmaceuticals Limited ,Pharmaceuticals Limited ,Radboud University Medical Centre ,Principal Investigator ,Telix Medical Director ,Middle East ,Biologics License Application ,United States Food ,Offering Compassionate Use ,Investigational Medicines ,European Economic Area ,Telix Pharmaceuticals Limited ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Biotechnology ,Clinical Trials Amp Medical Discoveries ,